A share price of Mirum Pharmaceuticals Inc [MIRM] is currently trading at $69.06, up 3.52%. An important factor to consider is whether the stock is rising or falling in short-term value. The MIRM shares have gain 6.52% over the last week, with a monthly amount glided 30.18%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
On April 17, 2024, Stifel initiated with a Buy rating and assigned a price target of $48 on the stock. H.C. Wainwright reiterated its Buy rating and decreased its price target to $58 on December 18, 2023. Morgan Stanley started tracking with a Overweight rating for this stock on November 13, 2023, and assigned it a price target of $60. In a note dated October 24, 2023, Cantor Fitzgerald initiated an Overweight rating and provided a target price of $50 on this stock.
Mirum Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $36.86 and $69.27. Currently, Wall Street analysts expect the stock to reach $85 within the next 12 months. Mirum Pharmaceuticals Inc [NASDAQ: MIRM] shares were valued at $69.06 at the most recent close of the market. An investor can expect a potential return of 23.08% based on the average MIRM price forecast.
Analyzing the MIRM fundamentals
Trailing Twelve Months sales for Mirum Pharmaceuticals Inc [NASDAQ:MIRM] were 429.16M which represents 64.09% growth. Gross Profit Margin for this corporation currently stands at 0.79% with Operating Profit Margin at -0.13%, Pretax Profit Margin comes in at -0.13%, and Net Profit Margin reading is -0.14%. To continue investigating profitability, this company’s Return on Assets is posted at -0.08, Equity is -0.25 and Total Capital is -0.1. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.25.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 67.06 points at the first support level, and at 65.06 for the second support level. However, for the 1st resistance point, the stock is sitting at 70.09, and for the 2nd resistance point, it is at 71.13.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Mirum Pharmaceuticals Inc [NASDAQ:MIRM] is 3.13. On the other hand, the Quick Ratio is 2.97, and the Cash Ratio is 1.58. Considering the valuation of this stock, the price to sales ratio is 8.08, the price to book ratio is 13.55.
Transactions by insiders
Recent insider trading involved Peetz Christopher, CHIEF EXECUTIVE OFFICER, that happened on Aug 11 ’25 when 40000.0 shares were sold. Officer, CHRISTOPHER PEETZ completed a deal on Aug 11 ’25 to buy 40000.0 shares. Meanwhile, SVP, GLOBAL CONTROLLER Howe Jolanda sold 10000.0 shares on Aug 07 ’25.
